Emcure Pharmaceuticals Partners With Roche to Expand CKD and Transplant Care in India

The deal, effective 1 April 2026, aims to broaden access to critical treatments for chronic kidney disease (CKD), anemia management, and transplant care. Financial terms of the agreement were not disclosed.

Emcure Pharmaceuticals has entered into a distribution agreement with Roche to supply select therapies in the nephrology and transplant medicine portfolio across India.

The deal, effective 1 April 2026, aims to broaden access to critical treatments for chronic kidney disease (CKD), anemia management, and transplant care. Financial terms of the agreement were not disclosed.

Under the agreement, Emcure will distribute Roche’s established brands, including Cellcept, a leading immunosuppressant supporting organ transplants globally since 1995, and Mircera and Neorecormon, therapies for anemia in CKD patients. Mircera, a long-acting erythropoiesis-stimulating agent (ESA), allows dosing once every 2–4 weeks.

Emcure, a recognized leader in anemia management, has an established presence in the nephrology and CKD segments through its subsidiaries. Roche’s portfolio complements Emcure’s existing offerings, creating a strategic alignment aimed at expanding access to these medicines across India.

Commenting on the agreement, Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals, said, “This partnership with Roche is a natural extension of Emcure’s commitment to improving outcomes in anemia and renal care. Roche’s globally trusted innovations strongly complement our existing portfolio and reach. Together, we aim to expand access to these critical therapies and support physicians in delivering optimal care to patients across India.”

Rajji Mehdwan, Managing Director & CEO, Roche India & Neighbouring Markets, added, “We are pleased to partner with Emcure Pharmaceuticals, a company with deep expertise and leadership in anemia management and nephrology. Through Emcure’s strong distribution network and clinical engagement, these medicines can reach a larger number of patients who can benefit from Roche’s long-standing innovations in transplant and CKD care.”

The collaboration is expected to enhance patient access to proven therapies while supporting improved anemia management and long-term outcomes for individuals with CKD and transplant needs in India.

Stay tuned for more such updates on Digital Health News